Analyst will focus on phase III studies and travel vaccines in Bavarian report

On Monday, Bavarian Nordic will release its first quarterly report for the year, and a Sydbank analyst is waiting in suspense to hear more about two phase III vaccine studies and how well travel vaccines performed.
Photo: Philip Davali/Ekstra Bladet, Philip Davali
Photo: Philip Davali/Ekstra Bladet, Philip Davali
by marketwire, translated by daniel pedersen

In the year 2022, Bavarian Nordic will be conducting two phase III studies – and investors are keeping a keen eye on news about either, when the biotech firm publicizes figures from its first financial quarterly on Monday.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading